Compounded Semaglutide & Tirzepatide vs. Ozempic, Wegovy, Mounjaro, and Zepbound: What's Actually Different
If you're researching GLP-1 medications, you've probably seen both brand names — Ozempic, Wegovy, Mounjaro, Zepbound — and the term "compounded semaglutide" or "compounded tirzepatide" used almost interchangeably online. They are not interchangeable, and the difference matters before you start treatment.
The most important fact first: Ozempic, Wegovy, Mounjaro, and Zepbound are FDA-approved finished drug products. Compounded semaglutide and compounded tirzepatide are not. That single distinction shapes everything else in this comparison.
Compounded Is Not the Same As, Equivalent To, or a Generic Version of the Brand-Name Product
This needs to be stated plainly, not softened: compounded semaglutide and compounded tirzepatide are not the same as, not equivalent to, and not a generic version of Ozempic, Wegovy, Mounjaro, or Zepbound.
"Generic" is a specific FDA regulatory category — a generic drug goes through its own FDA approval pathway confirming it matches the brand-name product's active ingredient, strength, dosage form, and bioequivalence. Compounded medications do not go through that pathway. They are prepared individually by a licensed pharmacy for a specific patient under a prescription, using the same class of active pharmaceutical ingredient, but they are not reviewed or approved by the FDA as a finished product, and they are not classified as generics.
Ozempic and Wegovy are brand-name semaglutide products manufactured by Novo Nordisk. Mounjaro and Zepbound are brand-name tirzepatide products manufactured by Eli Lilly. Bold You Wellness does not sell, distribute, or have any affiliation with Novo Nordisk, Eli Lilly, or any of these brand-name products. They're referenced here only to explain the regulatory landscape a patient is actually choosing between.
Side-by-Side: What's Actually Different
| Ozempic / Wegovy (Novo Nordisk) | Mounjaro / Zepbound (Eli Lilly) | Compounded Semaglutide / Tirzepatide | |
|---|---|---|---|
| FDA approval status | FDA-approved finished drug products | FDA-approved finished drug products | Not FDA-approved as a finished drug product; prepared by FDA-registered 503A/503B compounding pharmacies under individual prescription |
| Active ingredient class | Semaglutide — GLP-1 receptor agonist | Tirzepatide — dual GIP/GLP-1 receptor agonist | Same active ingredient classes (semaglutide or tirzepatide), compounded rather than manufactured as a finished branded product |
| Typical cost range* | Roughly $1,000–$1,350+/month list price before insurance or manufacturer savings programs | Roughly $1,000–$1,300+/month list price before insurance or manufacturer savings programs | $249–$339/month direct-pay through Bold You Wellness |
| Format options | Subcutaneous injection (Ozempic, Wegovy). Semaglutide is also available as brand-name Rybelsus, an oral tablet, for type 2 diabetes. | Subcutaneous injection only | Semaglutide: injection or oral sublingual tablet. Tirzepatide: injection. |
*Brand-name pricing reflects publicly available list pricing as of this writing and is subject to change; actual out-of-pocket cost varies significantly with insurance coverage, manufacturer savings cards, and pharmacy. Bold You Wellness makes no representation regarding the accuracy of third-party pricing and is not affiliated with Novo Nordisk or Eli Lilly.
Why the Cost Difference Exists
The cost gap here isn't a claim about which option works better — it reflects two different regulatory and manufacturing pathways. Brand-name manufacturers price finished, FDA-approved products that went through the full clinical trial and approval process, and that pricing is frequently negotiated against insurance formularies. Compounding pharmacies prepare medication to individual prescriptions using bulk active pharmaceutical ingredient, without that same finished-product approval pathway or brand-name marketing overhead — which is a meaningful part of why compounded pricing is typically lower. Lower cost is not evidence of equivalent outcomes; it's a reflection of a different regulatory category with a different cost structure.
What the Clinical Trial Data Actually Tells You
Wegovy's FDA approval for chronic weight management was supported by the STEP program of clinical trials, including STEP-1 (NEJM, 2021), in which participants averaged 14.9% body weight loss over 68 weeks. Zepbound's approval was supported by the SURMOUNT program, including SURMOUNT-1 (NEJM, 2022), in which participants averaged 22.5% body weight loss over 72 weeks.
These trials were conducted on the brand-name formulations. Compounded semaglutide and tirzepatide have not been independently studied in equivalent published clinical trials, and outcomes with a compounded formulation may differ from what was observed in these trials. We're citing this data because it's the most rigorous publicly available evidence for how this medication class performs generally — not as a claim that compounded formulations produce the same results. For a deeper look at how this data applies (and doesn't apply) to what a patient might expect, see our full breakdown of GLP-1 results.
Why Patients Consider Compounded Options
None of the above means compounded medication isn't a legitimate, clinically supervised option — it means going in with accurate expectations about what category of product you're getting. Patients typically consider compounded semaglutide or tirzepatide for reasons that are about access, not a belief that it's identical to the brand:
- Cost. The list-price gap between brand-name and compounded is substantial, and not everyone's insurance covers GLP-1 medications for weight loss.
- Format flexibility. Compounded semaglutide is available as an oral tablet in addition to injection — brand-name semaglutide's oral option (Rybelsus) is currently approved for type 2 diabetes, not weight management.
- Availability during shortages. Compounding has historically served as a supply option during periods when brand-name GLP-1 medications were on the FDA's drug shortage list. Compounding rules tighten once a shortage is resolved, so availability can change.
Any of these are legitimate reasons to ask your provider about compounded options — but they're reasons rooted in access and cost, not a claim that the outcome will be the same as what a brand-name trial participant experienced.
The Bottom Line
Ozempic, Wegovy, Mounjaro, and Zepbound are FDA-approved medications manufactured by Novo Nordisk and Eli Lilly. Compounded semaglutide and tirzepatide use the same class of active pharmaceutical ingredient but are prepared individually by compounding pharmacies and are not FDA-approved finished products, not generics, and not guaranteed to produce equivalent outcomes. A licensed provider — not a price comparison — should be the one confirming whether either pathway is appropriate for you.
Compounded medications are not FDA-approved finished drug products. Results may vary. Not all patients will qualify for treatment. Prescribing decisions are made solely by licensed independent clinicians based on individual medical evaluation. This is not medical advice.
Want to see if you qualify for a provider-supervised compounded GLP-1 program? Explore the Bold You Wellness weight loss program or check current pricing.